NIOX Group (LON:NIOX) Given New GBX 86 Price Target at Deutsche Bank Aktiengesellschaft

NIOX Group (LON:NIOX) had its target price decreased by Deutsche Bank Aktiengesellschaft from GBX 90 to GBX 86 in a report released on Wednesday morning, MarketBeat reports. Deutsche Bank Aktiengesellschaft currently has a buy rating on the stock.

NIOX Group Price Performance

LON NIOX opened at GBX 66 on Wednesday. NIOX Group has a 52-week low of GBX 53.40 and a 52-week high of GBX 77.60. The firm has a market capitalization of £275.81 million, a price-to-earnings ratio of 52.80 and a beta of 0.92. The company has a debt-to-equity ratio of 1.10, a current ratio of 6.31 and a quick ratio of 1.94. The company has a 50 day simple moving average of GBX 68.87 and a 200-day simple moving average of GBX 70.22.

Insider Buying and Selling at NIOX Group

In related news, insider Sarah Duncan bought 5,522 shares of NIOX Group stock in a transaction dated Wednesday, December 3rd. The shares were bought at an average cost of GBX 71 per share, for a total transaction of £3,920.62. Corporate insiders own 4.88% of the company’s stock.

About NIOX Group

NIOX Group plc is a medical technology company focused on improving the lives of millions of people suffering from respiratory health issues globally. NIOX develops and markets innovative, non-invasive diagnostic products for chronic airway diseases, primarily asthma and COPD. Its lead product, NIOX VERO®, enables the accurate measurement of fractional exhaled nitric oxide (FeNO), an established biomarker for airway inflammation, supporting better diagnosis, monitoring and management of asthma and COPD in clinical and research settings.

Headquartered in the UK and listed on the London Stock Exchange (ticker: NIOX), the company operates internationally, serving healthcare professionals in over 50 countries.